In tumours, constitutive activation of KRAS is achieved through point mutations at codons G12, G13 or Q61, which function to lock KRAS into the active GTP-bound state, and thus confer upon the cancer cells the proliferative and pro-survival effects of KRAS signaling [5]. Here, KRAS is linked to neoplasm.